DexCom Inc. presents a bullish thesis with a $27.07B market cap, trailing P/E of 30.1, EPS of $2.33, and TTM revenue of $4.82B reflecting 15% YoY quarterly revenue growth, underscoring robust demand for its continuous glucose monitoring systems amid rising diabetes prevalence.
Key catalysts include ongoing product launches such as next-generation CGM sensors, international market expansion, and sustained earnings momentum driven by 19.3% profit margins and 21.4% operating margins, positioning the company for continued adoption in diabetes management.
Risks encompass regulatory hurdles for new device approvals, intense competition from Abbott and Medtronic, and macroeconomic pressures on healthcare reimbursement; these are mitigated by DexCom's strong R&D pipeline, 35.6% ROE, and diversified global presence.
Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.
Get Deeper Analysis
Ask Theo anything about DXCM — earnings, valuation, technicals, or portfolio fit.
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Fundamental Snapshot
Revenue
4.8179B
EBITDA
1.2923B
Gross Profit
2.9632B
Operating Margin
21.4%
Profit Margin
19.3%
ROE
35.6%
Book Value
$7.66
Beta
1.443
52-Wk High
$89.98
52-Wk Low
$54.11
Avg Volume
6.8182M
PEG Ratio
1.3
Trading Data
Open
$68.28
Previous Close
$68.65
Day Range
$68.28 – $70.38
Volume
6.8658M
Shares Outstanding
385.873M
Analyst Target
$85.24
Frequently Asked Questions
What is DexCom's business model?
DexCom develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management, generating revenue primarily through device sales and subscriptions. With TTM revenue of $4.82B and no dividend yield, the model focuses on recurring sensor replacements and international expansion.
What are DexCom's main revenue sources?
Revenue comes mainly from CGM hardware and disposable sensors, with TTM revenue at $4.82B showing 15% YoY growth. The company reports 19.3% profit margins, supported by high-margin recurring sensor sales rather than one-time device purchases.
What are DexCom's competitive advantages?
DexCom holds advantages through its specialized CGM technology, 35.6% ROE, and 21.4% operating margins, differentiating it from broader medical device peers. Its 1.44 beta reflects growth-oriented positioning in the $27.07B market cap healthcare sector.
What are the key risks for DXCM investors?
Key risks include regulatory approval delays, competition from Abbott and Medtronic, and reimbursement changes, with a forward P/E of 26.81 indicating valuation sensitivity. Mitigations involve ongoing innovation and a 30.1 trailing P/E supported by earnings growth.
What is the growth outlook for DXCM?
Growth outlook remains positive with 15% YoY revenue growth, EPS of $2.33, and analyst target price of $85.24. The company benefits from expanding CGM adoption, though investors should monitor quarterly earnings dates and the absence of dividends.
